Olverembatinib, a multikinase inhibitor that modulates lipid metabolism, in advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 1b study and translational research
9.0
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-04 11:32
摘要：
Olverembatinib, a novel multikinase inhibitor, has shown significant antitumor activity in patients with advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors (GISTs). In a multicenter phase 1b study, it demonstrated a median progression-free survival of 25.7 months and a clinical benefit rate of 84.6%. The study highlights olverembatinib's ability to modulate lipid metabolism and inhibit tumorigenic pathways, marking it as a promising candidate for early investment in oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
1.0
关键证据
Olverembatinib was well tolerated with a clinical benefit rate of 84.6%.
The median progression-free survival was 25.7 months for SDH-deficient GISTs.
This is the largest prospective clinical trial for this rare GIST subtype.
真实性检查
否
AI评分总结
Olverembatinib, a novel multikinase inhibitor, has shown significant antitumor activity in patients with advanced succinate dehydrogenase-deficient gastrointestinal stromal tumors (GISTs). In a multicenter phase 1b study, it demonstrated a median progression-free survival of 25.7 months and a clinical benefit rate of 84.6%. The study highlights olverembatinib's ability to modulate lipid metabolism and inhibit tumorigenic pathways, marking it as a promising candidate for early investment in oncology.